Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Retained Earnings (2018 - 2025)

BioNexus Gene Lab's Retained Earnings history spans 8 years, with the latest figure at -$112547.0 for Q3 2025.

  • For Q3 2025, Retained Earnings rose 30.55% year-over-year to -$112547.0; the TTM value through Sep 2025 reached -$112547.0, up 30.55%, while the annual FY2024 figure was -$3.4 million, 408.29% down from the prior year.
  • Retained Earnings for Q3 2025 was -$112547.0 at BioNexus Gene Lab, up from -$4.7 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $1.3 million in Q3 2022 and bottomed at -$4.7 million in Q2 2025.
  • The 5-year median for Retained Earnings is -$448101.0 (2023), against an average of -$766892.6.
  • The largest YoY upside for Retained Earnings was 1043.56% in 2022 against a maximum downside of 491.84% in 2022.
  • A 5-year view of Retained Earnings shows it stood at -$100262.0 in 2021, then tumbled by 307.99% to -$409062.0 in 2022, then crashed by 65.57% to -$677294.0 in 2023, then crashed by 408.29% to -$3.4 million in 2024, then skyrocketed by 96.73% to -$112547.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Retained Earnings are -$112547.0 (Q3 2025), -$4.7 million (Q2 2025), and -$482841.0 (Q1 2025).